Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Sirtuin inhibitors find play as anti-cancer agents
September 2007
SHARING OPTIONS:

BOULDER, Colo. and MONTREAL—Pharmion Corp. and MethylGene Inc. have entered a research collaboration for the development of novel small-molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death. Pharmion and MethylGene's Class I-specific HDAC inhibitor, MGCD0103, has demonstrated efficacy in a number of tumor types, and the sirtuins represent potentially attractive novel cancer targets within a related family of enzymes.
This agreement expands the January 2006 license and collaboration agreement between Pharmion and MethylGene for the research, development and commercialization of MethylGene's oncology HDAC inhibitors, led by MGCD0103, currently in Phase II clinical trials. Sirtuin inhibitors, the third epigenetic modality to be explored for anticancer activity by Pharmion, and the second in collaboration with MethylGene, are expected to be studied both as monotherapy and combination therapy in the treatment of cancer once a clinical candidate is identified. MethylGene has already identified a series of potent lead compounds, and Pharmion expects to file an initial IND application within the next 24 to 30 months.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.